Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only.All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

4X Blend_GHRP-2 Tesamorelin MGF Ipamorelin_5MG5MG500MCG2.5MG

4X Blend (GHRP-2 + Tesamorelin + MGF + Ipamorelin)

The 4X Blend is a multi-component peptide formulation combining four well-characterized research peptides—GHRP-2, Tesamorelin, Mechano Growth Factor (MGF), and Ipamorelin—into a single lyophilized preparation for advanced laboratory investigation. This blend is designed for researchers studying coordinated growth hormone signaling, peptide synergy, and anabolic or regenerative signaling pathways in controlled experimental models.*

Each component of the 4X Blend has been independently studied in scientific literature for its role in growth hormone release, receptor-mediated signaling, and tissue-level cellular communication. When combined, these peptides provide a comprehensive research platform for exploring interactions between GHRH analogs, ghrelin receptor agonists, and IGF-1–related growth factor fragments.*

Key Specifications

  • Blend Name: 4X Blend
  • Peptide Components:
    • 5mg GHRP-2 (Growth Hormone-Releasing Peptide-2)
    • 5mg Tesamorelin (GHRH analog)
    • 500mcg Mechano Growth Factor (MGF / IGF-1Ec fragment)
    • 2.mg Ipamorelin (Selective ghrelin mimetic)
  • Form: Lyophilized powder
  • Purity: ≥99% (individual components, HPLC verified)
  • Analytical Verification: HPLC and Mass Spectrometry (MS)
  • Manufacturing: Solid-phase peptide synthesis with in-house purification

$90.00

$85.50 each
$81.00 each

Products will arrive in a lyophilized (powder) form for maximum stability.

Free domestic shipping on orders over $300

4X Blend (GHRP-2 + Tesamorelin + MGF + Ipamorelin)

Scientific & Research Context

The 4X Blend integrates peptides that act through distinct but complementary biological pathways commonly examined in endocrine, metabolic, and musculoskeletal research.*

  • Tesamorelin is a stabilized growth hormone-releasing hormone (GHRH) analog frequently used to study pituitary GH pulsatility and downstream IGF-1 signaling.*

  • GHRP-2 and Ipamorelin are ghrelin receptor (GHS-R1a) agonists investigated for their ability to stimulate GH release through non-GHRH mechanisms, allowing researchers to examine dual-pathway activation models.*

  • MGF (IGF-1Ec) is a splice variant–derived peptide fragment studied in muscle biology and mechanotransduction research, particularly in models of tissue repair and cellular growth signaling.*

In laboratory research environments, the 4X Blend has been utilized to investigate:*

  • Coordinated stimulation of growth hormone signaling pathways

  • Synergistic interactions between GHRH analogs and ghrelin mimetics

  • Peptide-mediated modulation of IGF-1–related signaling cascades

  • Cellular responses involved in muscle, connective tissue, and metabolic research

  • Structure–function relationships across multiple peptide classes

This multi-peptide format allows researchers to evaluate complex signaling dynamics within a single experimental system while maintaining consistent peptide sourcing and analytical quality.*

Quality & Analytical Assurance

Each peptide included in the 4X Blend is synthesized using validated solid-phase peptide synthesis techniques and purified to high analytical standards. Batch verification is performed using HPLC and mass spectrometry to confirm molecular identity, sequence integrity, and purity, ensuring reproducibility and consistency across research applications.

Storage & Handling

The 4X Blend is supplied in lyophilized form to support stability during shipping and long-term storage. Store unopened vials in a cool, dry environment protected from light. Reconstitution and handling should follow established peptide research protocols and laboratory best practices to preserve molecular integrity.*

For further information on proper storage techniques, click the button…

Storage Instructions

Referenced Scientific Literature
Provided for informational and educational purposes only

  • Bowers CY, Momany FA, Reynolds GA, Hong A. “On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.” Endocrinology, 1984.
  • Smith RG, Van der Ploeg LHT, Howard AD, et al. “Peptidomimetic regulation of growth hormone secretion.” Endocrine Reviews, 1997.
  • Laferrère B, Abraham C, Russell CD, Bowers CY. “Growth hormone–releasing peptide-2, like ghrelin, increases food intake in healthy men.” Journal of Clinical Endocrinology & Metabolism, 2005.
  • Muccioli G, Papotti M, Locatelli V, et al. “Growth hormone secretagogues and the cardiovascular system.” Annales d’Endocrinologie, 2000.
  • Alba M, Schally AV, et al. “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone analog, normalizes growth in GHRH knockout mice.” American Journal of Physiology – Endocrinology and Metabolism, 2006.
  • Ionescu M, Frohman LA. “Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295.” Journal of Clinical Endocrinology & Metabolism, 2006.
  • Falutz J, Mamputu JC, et al. “Metabolic effects of a growth hormone–releasing factor analog in humans.” New England Journal of Medicine, 2007.
  • Goldspink G. “Mechanical signals, IGF-I gene splicing, and muscle adaptation.” Physiology, 2005.
  • Hill M, Wernig A, Goldspink G. “Muscle satellite cell activation by IGF-1 splice variants.” Journal of Physiology, 2003.
  • Matheny RW, Nindl BC, Adamo ML. “Mechano growth factor and IGF-I signaling in skeletal muscle.” Growth Hormone & IGF Research, 2010.
  • Raun K, Hansen BS, Johansen NL, et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology, 1998.
  • Svensson J, Lönn L, et al. “GH secretagogues increase bone mineral content in adult rats.” Journal of Endocrinology, 2000.
  • Adeghate E, Ponery AS. “Mechanism of ipamorelin-evoked insulin release from the pancreas.” Neuroendocrinology Letters, 2004.
  • Moulin A, Ryan J, Martinez J, Fehrentz JA. “Recent developments in ghrelin receptor ligands.” ChemMedChem, 2007.
  • Taub DD, Murphy WJ, Longo DL. “Rejuvenation of the aging thymus: growth hormone–mediated and ghrelin-mediated signaling pathways.” Current Opinion in Pharmacology, 2010.
  • Jetté L, Thibaudeau K, et al. “Identification of CJC-1295 as a long-lasting GRF analog.” Endocrinology, 2005.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.